NexgenRx Beheer

Beheer criteriumcontroles 2/4

De CEO NexgenRx is Ron Loucks, benoemd in Mar2003, heeft een ambtstermijn van 21.67 jaar. De totale jaarlijkse vergoeding van { bedraagt CA$ 313.34K, bestaande uit 75% salaris en 25% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 10.48% van de aandelen van het bedrijf, ter waarde CA$ 2.20M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 5.5 jaar en 12.5 jaar.

Belangrijke informatie

Ron Loucks

Algemeen directeur

CA$313.3k

Totale compensatie

Percentage CEO-salaris	75.0%
Dienstverband CEO	21.7yrs
Eigendom CEO	10.5%
Management gemiddelde ambtstermijn	5.5yrs
Gemiddelde ambtstermijn bestuur	12.5yrs

Recente managementupdates

We Discuss Why NexgenRx Inc.'s (CVE:NXG) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year

May 10

Recent updates

Optimistic Investors Push NexgenRx Inc. (CVE:NXG) Shares Up 45% But Growth Is Lacking

May 21

We Discuss Why NexgenRx Inc.'s (CVE:NXG) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year

May 10

NexgenRx Inc.'s (CVE:NXG) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Feb 19

How Much Is NexgenRx's (CVE:NXG) CEO Getting Paid?

Dec 28

Analyse CEO-vergoeding

Hoe is Ron Loucks's beloning veranderd ten opzichte van NexgenRx's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-CA$25k
Mar 31 2024	n/a	n/a	-CA$66k
Dec 31 2023	CA$313k	CA$235k	-CA$332k
Sep 30 2023	n/a	n/a	-CA$310k
Jun 30 2023	n/a	n/a	-CA$244k
Mar 31 2023	n/a	n/a	-CA$172k
Dec 31 2022	CA$287k	CA$235k	-CA$22k
Sep 30 2022	n/a	n/a	CA$3m
Jun 30 2022	n/a	n/a	CA$4m
Mar 31 2022	n/a	n/a	CA$4m
Dec 31 2021	CA$230k	CA$215k	CA$4m
Sep 30 2021	n/a	n/a	CA$2m
Jun 30 2021	n/a	n/a	CA$2m
Mar 31 2021	n/a	n/a	CA$2m
Dec 31 2020	CA$153k	CA$140k	CA$2m
Sep 30 2020	n/a	n/a	CA$1m
Jun 30 2020	n/a	n/a	CA$483k
Mar 31 2020	n/a	n/a	-CA$31k
Dec 31 2019	CA$181k	CA$165k	-CA$208k
Sep 30 2019	n/a	n/a	CA$38k
Jun 30 2019	n/a	n/a	-CA$147k
Mar 31 2019	n/a	n/a	-CA$438k
Dec 31 2018	CA$181k	CA$165k	-CA$697k
Sep 30 2018	n/a	n/a	-CA$1m
Jun 30 2018	n/a	n/a	-CA$1m
Mar 31 2018	n/a	n/a	-CA$793k
Dec 31 2017	CA$181k	CA$165k	-CA$626k

Compensatie versus markt: De totale vergoeding ($USD 222.40K ) Ron } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Canadian markt ($USD 170.34K ).

Compensatie versus inkomsten: De vergoeding van Ron is gestegen terwijl het bedrijf verliesgevend is.

CEO

Ron Loucks (74 yo)

21.7yrs

Tenure

CA$313,342

Compensatie

Mr. Ronald C. Loucks, also known as Ron, B.B.A. Founded NexgenRx, Inc. in March 2003 and has been its Chief Executive Officer and President since March 2003. Mr. Loucks has over 25 years of experience in t...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Ronald Loucks	Founder	21.7yrs	CA$313.34k	10.48% CA$ 2.2m
Kelly Elher	Chief Financial Officer	7.5yrs	CA$60.00k	0.63% CA$ 132.5k
Andrew Munroe	Vice President of Operations	less than a year	CA$169.40k	geen gegevens
Jason Robinson	Vice President of Administration	no data	geen gegevens	geen gegevens
Doreen Harvey	Lead Human Resources	no data	geen gegevens	geen gegevens
Paul Bolger	Company Secretary	3.4yrs	geen gegevens	geen gegevens
Avik Debroy	Financial Controller	no data	geen gegevens	geen gegevens

5.5yrs

Gemiddelde duur

Ervaren management: Het managementteam van NXG is doorgewinterd en ervaren (gemiddelde ambtstermijn van 5.5 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Ronald Loucks	Founder	21.7yrs	CA$313.34k	10.48% CA$ 2.2m
Thomas Corcoran	Independent Chairman	18.7yrs	CA$30.00k	0.88% CA$ 184.5k
Linda Brennan	Director	less than a year	geen gegevens	geen gegevens
Randolf McGlynn	Independent Director	6.3yrs	CA$20.00k	0.14% CA$ 29.5k

12.5yrs

Gemiddelde duur

74yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van NXG zijn ervaren en ervaren (gemiddelde ambtstermijn van 12.5 jaar).

NexgenRx Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

NexgenRx Inc. Announces Appointment of Linda Brennan to Its Board of Directors

Charles Burns Tenders Resignation as Director of NexgenRx Inc

We Discuss Why NexgenRx Inc.'s (CVE:NXG) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year

NexgenRx Inc., Annual General Meeting, May 16, 2024

Insufficient new directors

NEXGENRX INC. Announces the Retirement of Dave Bennett from its Board of Directors

Recent updates

NexgenRx Inc. Announces Appointment of Linda Brennan to Its Board of Directors

New major risk - Revenue and earnings growth

Second quarter 2024 earnings released: EPS: CA$0 (vs CA$0 in 2Q 2023)

Dividend of CA$0.005 announced

NexgenRx Inc. Declares Dividend in Respect of All of Its Outstanding Common Shares, Payable on or Before June 30, 2024

Optimistic Investors Push NexgenRx Inc. (CVE:NXG) Shares Up 45% But Growth Is Lacking

First quarter 2024 earnings released: EPS: CA$0.006 (vs CA$0.003 in 1Q 2023)

Charles Burns Tenders Resignation as Director of NexgenRx Inc

We Discuss Why NexgenRx Inc.'s (CVE:NXG) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year

Full year 2023 earnings released: CA$0.005 loss per share (vs CA$0 in FY 2022)

NexgenRx Inc., Annual General Meeting, May 16, 2024

NexgenRx Inc.'s (CVE:NXG) Price Is Out Of Tune With Revenues

Insufficient new directors

NEXGENRX INC. Announces the Retirement of Dave Bennett from its Board of Directors

NEXGENRX Inc Announces Declaration of Dividend, Payable on or Before January 4, 2024

Third quarter 2023 earnings released: CA$0.002 loss per share (vs CA$0.001 loss in 3Q 2022)

Second quarter 2023 earnings released: EPS: CA$0 (vs CA$0 in 2Q 2022)

NexgenRx Inc. Announces Declaration of Dividend in Respect of All of Its Outstanding Common Shares , Payable on or Before June 30, 2023

High number of new directors

First quarter 2023 earnings released: EPS: CA$0.003 (vs CA$0.005 in 1Q 2022)

NexgenRx Inc. Appoints Dave Bennett as New Director

Insufficient new directors

Full year 2022 earnings released

Here's Why We Think NexgenRx (CVE:NXG) Might Deserve Your Attention Today

Insufficient new directors

Now 23% undervalued

Third quarter 2022 earnings released

Insufficient new directors

Is Now The Time To Put NexgenRx (CVE:NXG) On Your Watchlist?

NexgenRx Inc. Announces Dividend on its outstanding common shares, payable on or Before October 10, 2022

NexgenRx Inc. Announces Dividend on its outstanding common shares, Payable on Payable on or Before October 10, 2022

Second quarter 2022 earnings released: CA$0.001 loss per share (vs CA$0.005 profit in 2Q 2021)

First quarter 2022 earnings released: EPS: CA$0.005 (vs CA$0.005 in 1Q 2021)

Insufficient new directors

NexgenRx Inc., Annual General Meeting, May 19, 2022

Full year 2021 earnings released: EPS: CA$0.055 (vs CA$0.029 in FY 2020)

Does NexgenRx (CVE:NXG) Deserve A Spot On Your Watchlist?

Third quarter 2021 earnings released: EPS CA$0.006 (vs CA$0.007 in 3Q 2020)

Insufficient new directors

What NexgenRx Inc.'s (CVE:NXG) 32% Share Price Gain Is Not Telling You

Second quarter 2021 earnings released: EPS CA$0.005 (vs CA$0.007 in 2Q 2020)

Here's Why NexgenRx Inc.'s (CVE:NXG) CEO May Have Their Pay Bumped Up

First quarter 2021 earnings released: EPS CA$0.005 (vs CA$0.004 in 1Q 2020)

Full year 2020 earnings released: EPS CA$0.03 (vs CA$0.003 loss in FY 2019)

New 90-day high: CA$0.34

NexgenRx Inc.'s (CVE:NXG) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

New 90-day high: CA$0.30

How Much Is NexgenRx's (CVE:NXG) CEO Getting Paid?

New 90-day high: CA$0.23

Third quarter 2020 earnings released: EPS CA$0.007

NexgenRx Inc.(TSXV:NXG) dropped from S&P/TSX Venture Composite Index

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd